DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. There are four patents protecting this drug.
This drug has twenty-eight patent family members in ten countries.
The generic ingredient in QINLOCK is ripretinib. Additional details are available on the ripretinib profile page.
Qinlock will be eligible for patent challenges on May 15, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 7, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
DrugPatentWatch® Estimated Generic Entry Opportunity Date for qinlock
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for qinlock
Identify potential brand extensions & 505(b)(2) entrants
|Deciphera Pharmaceuticals LLC||Phase 1|
|Country||Patent Number||Estimated Expiration|
|Australia||2007296441||⤷ Free Forever Trial|
|China||101516379||⤷ Free Forever Trial|
|Eurasian Patent Organization||026730||⤷ Free Forever Trial|
|Brazil||PI0716981||⤷ Free Forever Trial|
|European Patent Office||2063897||⤷ Free Forever Trial|
|Eurasian Patent Organization||016055||⤷ Free Forever Trial|
|Eurasian Patent Organization||200970279||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|